Vivos Therapeutics reports Q4 revenue $4.0M, FY revenue $16.0M; appliance sales up 21% in Q4

Vivos Therapeutics, Inc.

Q4 2022 revenue $4.0M vs $4.4M YoY; full-year revenue $16.0M vs $16.9M; $2.5M revenue deferred under ASC 606.
Q4 appliance arches sold 2,938 (+21% YoY); full-year 12,281 (+8% YoY).
Gross margin 60% in Q4 (vs 71% YoY) and 63% for FY (vs 75% YoY) due to higher costs and new incentives.
Cash $3.5M at Dec 31, 2022; raised ~$7.4M net in Jan 2023 private placement.
Received FDA 510(k) clearance for DNA appliance for mild-to-moderate OSA; acquired patents from Advanced Facialdontics for TMD/Bruxism.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.65

Vivos Therapeutics, Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue $4.0 million for the fourth quarter of 2022 and $16.0 million for the full year ended December 31, 2022.

Period: fourth quarter and fiscal year ended December 31, 2022
Revenue: $4.0 million for the fourth quarter of 2022 and $16.0 million for the full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 30, 2023, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-009837

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.